Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 4/2024

19-02-2024 | Anthracycline

A Comprehensive Review of Cancer Drug–Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies

Authors: Vincenzo Costanzo, PhD, Yashwant Kumar Ratre, PhD, Emanuela Andretta, PhD, Rakesh Acharya, M.sc Zoology, L. V. K. S. Bhaskar, PhD, Henu Kumar Verma, PhD

Published in: Current Treatment Options in Oncology | Issue 4/2024

Login to get access

Opinion statement

Cardiotoxicity has emerged as a serious outcome catalyzed by various therapeutic targets in the field of cancer treatment, which includes chemotherapy, radiation, and targeted therapies. The growing significance of cancer drug–induced cardiotoxicity (CDIC) and radiation-induced cardiotoxicity (CRIC) necessitates immediate attention. This article intricately unveils how cancer treatments cause cardiotoxicity, which is exacerbated by patient-specific risks. In particular, drugs like anthracyclines, alkylating agents, and tyrosine kinase inhibitors pose a risk, along with factors such as hypertension and diabetes. Mechanistic insights into oxidative stress and topoisomerase-II-B inhibition are crucial, while cardiac biomarkers show early damage. Timely intervention and prompt treatment, especially with specific agents like dexrazoxane and beta-blockers, are pivotal in the proactive management of CDIC.
Literature
1.
Kumar D, et al. Automatic detection of white blood cancer from bone marrow microscopic images using convolutional neural networks. IEEE Access. 2020;8:142521–31.CrossRef
2.
• Advancing Cancer Therapy. Nature Cancer. 2021;2(3):245–6. This article mentioned detailed view of recent updated cancer treatment option.CrossRef
3.
4.
5.
Curigliano G, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–90.PubMedCrossRef
6.
7.
Ginzac A, et al. Treatment-induced cardiotoxicity in breast cancer: a review of the interest of practicing a physical activity. Oncology. 2019;96(5):223–34.PubMedCrossRef
8.
Albini A, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14–25.PubMedPubMedCentralCrossRef
9.
Blanco JG, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(13):1415.PubMedCrossRef
10.
Pavo N, et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015;101(23):1874–80.PubMedCrossRef
11.
Lipshultz SE, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332(26):1738–44.PubMedCrossRef
12.
Krischer JP, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15(4):1544–52.PubMedCrossRef
13.
Ezaz G, et al. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3(1):e000472.PubMedPubMedCentralCrossRef
14.
Herrmann J, et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014. Elsevier.
15.
Fogarassy G, et al. Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer–a real-world data-based, nationwide classification analysis. Int J Cardiol. 2019;285:47–52.PubMedCrossRef
16.
Curigliano G, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii155-66.PubMedCrossRef
17.
Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011;3(1):1351–71.PubMedCrossRef
18.
Finet JE, Tang WHW. Protecting the heart in cancer therapy. F1000Res. 2018;28(7).
19.
Didagelos M, et al. Bleomycin cardiotoxicity during chemotherapy for an ovarian germ cell tumor. Hippokratia. 2013;17(2):187–8.PubMedPubMedCentral
20.
Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(8):1091–110.CrossRef
21.
Battisti NML, et al. Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience. Breast Cancer Res Treat. 2019;178(2):401–8.PubMedCrossRef
22.
23.
Shacham-Abulafia A, et al. Real-life experience with ponatinib in chronic myeloid leukemia: a multicenter observational study. Clin Lymphoma Myeloma Leuk. 2018;18(7):e295–301.PubMedCrossRef
24.
Procopio G, et al. Sorafenib versus observation following radical metastasectomy for clear-cell renal cell carcinoma: results from the phase 2 randomized open-label RESORT study. Eur Urol Oncol. 2019;2(6):699–707.PubMedCrossRef
25.
Khaled H, et al. A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma. Mol Clin Oncol. 2015;3(5):1099–102.PubMedPubMedCentralCrossRef
26.
Lee JL, et al. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann Oncol. 2015;26(11):2300–5.PubMedCrossRef
27.
Fausto C, et al. Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. Haematologica. 2016;101(10):1200–7.CrossRef
28.
Ganatra S, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018;4(12):1491–500.PubMedCrossRef
29.
Grothey A, et al. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev. 2020;86(101993):20.
30.
de Lavallade H, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358–63.PubMedCrossRef
31.
32.
•• Kamaraju S, et al. Interactions between cardiology and oncology drugs in precision cardio-oncology. Clin Sci. 2021;135(11):1333–51. Mentioned about detailed interactions of cardiology and oncology drugs in precision medicine.CrossRef
33.
Xu B, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351–60.PubMedCrossRef
34.
Hauschild A, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.PubMedCrossRef
35.
36.
37.
Valenzuela MM, Neidigh JW, Wall NR. Antimetabolite treatment for pancreatic cancer. Chemotherapy. 2014;3(3):2167–7700.
38.
Sethy C, Kundu CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother. 2021;137:111285.PubMedCrossRef
39.
Isakoff SJ, et al. Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study. Br J Cancer. 2014;111(11):2058–66.PubMedPubMedCentralCrossRef
40.
41.
Stoicescu EA, et al. Docetaxel for breast cancer treatment-side effects on ocular surface, a systematic review. Processes. 2021;9(7):1086.CrossRef
42.
43.
44.
Dhyani P, et al. Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine. Cancer Cell Int. 2022;22(1):206.PubMedPubMedCentralCrossRef
45.
• Jayaweera SPE, et al. Carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Front Oncol. 2021;11(740796). This article shows the importance of carfilzomib for the treatment of relapsed and refractory multiple myeloma patients.
46.
Reneau JC, et al. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: a propensity matched study of 1,790 patients. Am J Hematol. 2017;92(2):E15–7.
47.
Jouni H, et al. Ixazomib cardiotoxicity: a possible class effect of proteasome inhibitors. Am J Hematol. 2017;92(2):220–1.PubMedCrossRef
48.
Stenehjem JS, et al. Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation. Br J Cancer. 2016;115(2):178–87.PubMedPubMedCentralCrossRef
49.
Russo F, et al. The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. BMC Cancer. 2013;13(1):56.PubMedPubMedCentralCrossRef
50.
Saleem T, Kasi A. Daunorubicin. Aug 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
51.
Madeddu C, et al. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. J Cardiovasc Med. 2016;17(1):0000000000000376.
52.
Neelapu SS, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer. 2020;8(2):2020–001235.CrossRef
53.
•• Wang H, et al. Breaking the bottleneck in anticancer drug development: Efficient Utilization of Synthetic Biology. Molecules. 2022;27(21):7480. Article is highly recommended due to its important role in anticancer drug development.
54.
Hortobagyi GJD. Anthracyclines in the treatment of cancer. Drugs. 1997;54(4):1–7.PubMed
55.
Bhutani M, et al. Randomized study comparing 4′-epi-doxorubicin (Epirubicin) versus doxorubicin as a part of induction treatment in adult acute lymphoblastic leukemia. Am J Hematol. 2002;71(4):241–7.PubMedCrossRef
56.
Megías-Vericat JE, et al. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. Expert Rev Clin Pharmacol. 2019;12(3):197–218.PubMedCrossRef
57.
Abraham R, Basser RL, Green MD. A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy. Drug Safety. 1996;15(6):406–29.PubMedCrossRef
58.
59.
Von Hoff DD, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710–7.CrossRef
60.
Alexander J, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979;300(6):278–83.PubMedCrossRef
61.
62.
Di Meo S, et al. Role of ROS and RNS sources in physiological and pathological conditions. Oxid Med Cell Longev. 2016;2016:1245049.PubMedPubMedCentral
63.
Vara D, Pula G. Reactive oxygen species: physiological roles in the regulation of vascular cells. Curr Mol Med. 2014;14(9):1103–25.PubMedCrossRef
64.
Mikhed Y, et al. Redox regulation of genome stability by effects on gene expression, epigenetic pathways and DNA damage/repair. Redox Biol. 2015;5:275–89.PubMedPubMedCentralCrossRef
65.
Salvatorelli E, Menna P, Minotti G. Managing anthracycline-induced cardiotoxicity: beginning with the end in mind. Futur Cardiol. 2015;11(4):363–6.CrossRef
66.
Mercurio V, et al. Models of heart failure based on the cardiotoxicity of anticancer drugs. J Card Fail. 2016;22(6):449–58.PubMedCrossRef
67.
Minotti G, et al. Pharmacological foundations of cardio-oncology. J Pharmacol Exp Ther. 2010;334(1):2–8.PubMedCrossRef
68.
Liu Y-Y, et al. Bacillus Calmette-Guerin and TLR4 agonist prevent cardiovascular hypertrophy and fibrosis by regulating immune microenvironment. J Immunol. 2008;180(11):7349–57.PubMedCrossRef
69.
Vejpongsa P. ETH Yeh, and Therapeutics, Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther. 2014;95(1):45–52.PubMedCrossRef
70.
Porto A, et al. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J. 2006;20(14):2565–6.PubMedCrossRef
71.
72.
Birks EJ, et al. Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant. 2004;23(2):228–35.PubMedCrossRef
73.
Armenian SH, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911.PubMedCrossRef
74.
Legha SS, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96(2):133–9.PubMedCrossRef
75.
Lipshultz SE, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91–01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol. 2002;20(6):1677–82.PubMedCrossRef
76.
Plana JC, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;15(10):1063–93.
77.
Gershwin ME, Goetzl EJ, Steinberg AD. Cyclophosphamide: use in practice. Ann Intern Med. 1974;80(4):531–40.PubMedCrossRef
78.
Zhao J, et al. High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. Leuk Lymphoma. 2021;62(5):1195–202.PubMedCrossRef
79.
Sullivan MP, Ramirez I. Curability of Burkitt’s lymphoma with high-dose cyclophosphamide-high-dose methotrexate therapy and intrathecal chemoprophylaxis. J Clin Oncol. 1985;3(5):627–36.PubMedCrossRef
80.
Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73(6):881–95.PubMedCrossRef
81.
Skarin AT, et al. Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). Blood. 1977;49(5):759–70.PubMed
82.
83.
Livingston R, et al. Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. Ann Intern Med. 1978;88(2):194–9.PubMedCrossRef
84.
Eder JP, et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol. 1986;4(11):1592–7.PubMedCrossRef
85.
Gottdiener JS, et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141(6):758–63.PubMedCrossRef
86.
Dow E, Schulman H. E Agura, Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant. 1993;12(2):169–72.PubMed
87.
Goldberg MA, et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986;68(5):1114–8.PubMedCrossRef
88.
89.
Buja LM, Ferrans VJ, Graw RG Jr. Cardiac pathologic findings in patients treated with bone marrow transplantation. Human Pathol. 1976;7(1):17–45.CrossRef
90.
Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971–9.PubMedCrossRef
91.
92.
Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res. 2010;106(1):21–34.PubMedCrossRef
93.
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353(2):172–87.PubMedCrossRef
94.
Osborn M, Hughes T. Managing imatinib resistance in chronic myeloid leukaemia. Curr Opin Hematol. 2010;17(2):97–103.PubMedCrossRef
95.
Cortes JE, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–7.PubMedCrossRef
96.
Hazarika M, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome–positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res. 2008;14(17):5325–31.PubMedCrossRef
97.
Lee W-S, Kim JM. Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy. Mol Cell Toxicol. 2018;14(3):247–54.CrossRef
98.
99.
Montani D, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–37.PubMedCrossRef
100.
101.
Weatherald J, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J. 2017;50(1):1700217.PubMedCrossRef
102.
Alkhatib Y, et al. The role of tyrosine kinase inhibitor “Lapatinib” in pulmonary hypertension. Pulm Pharmacol Ther. 2016;37:81–4.PubMedCrossRef
103.
Quilot F-M, et al. Pulmonary hypertension associated with ponatinib therapy. Eur Respir J. 2016;47(2):676–9.PubMedCrossRef
104.
Zakrzewski D, et al. Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia. Int J Hematol. 2012;96(1):132–5.PubMedCrossRef
105.
Mourad J-J, et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19(5):927–34.PubMedCrossRef
106.
Veronese ML, et al. Mechanisms of hypertension associated with BAY 43–9006. J Clin Oncol. 2006;24(9):1363–9.PubMedCrossRef
107.
Escudier B, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11.PubMedCrossRef
108.
Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.PubMedCrossRef
109.
Kerkelä R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908–16.PubMedCrossRef
110.
Cheng H, Force T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis. 2010;53(2):114–20.PubMedCrossRef
111.
Kerkela R, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci. 2009;2(1):15–25.PubMedPubMedCentralCrossRef
112.
Zamorano JL, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801.PubMedCrossRef
113.
Kantarjian H, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome–positive ALL. N Engl J Med. 2006;354(24):2542–51.PubMedCrossRef
114.
Ponte ML, Keller GA, Girolamo G. Mechanisms of drug induced QT interval prolongation. Curr Drug Saf. 2010;5(1):44–53.PubMedCrossRef
115.
Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21(19):3609–15.PubMedCrossRef
116.
Lee C-S, Rattu MA, Kim SS. A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib. J Oncol Pharm Pract. 2016;22(1):92–104.PubMedCrossRef
117.
Giudice V, Vecchione C, Selleri CJL. Cardiotoxicity of novel targeted hematological therapies. Life (Basel). 2020;10(12):344.PubMed
118.
Burger JA, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787–98.PubMedCrossRef
119.
McMullen JR, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829–30.PubMedCrossRef
120.
Fradley MG, et al. Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy. Am J Cardiol. 2019;124(4):539–44.PubMedCrossRef
121.
122.
McMullen JR, et al. Protective effects of exercise and phosphoinositide 3-kinase (p110α) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA. 2007;104(2):612–7.PubMedPubMedCentralCrossRef
123.
Pretorius L, et al. Reduced phosphoinositide 3-kinase (p110α) activation increases the susceptibility to atrial fibrillation. Am J Pathol. 2009;175(3):998–1009.PubMedPubMedCentralCrossRef
124.
• Sayegh N, et al. Cardiovascular toxicities associated with tyrosine kinase inhibitors. Curr Cardiol Rep. 2023;25(4):269–80. Important article mentioned about cardiovascular toxicities associated with TKI.PubMedPubMedCentralCrossRef
125.
126.
Rutledge CA, et al. c-Src kinase inhibition reduces arrhythmia inducibility and connexin43 dysregulation after myocardial infarction. J Am Coll Cardiol. 2014;63(9):928–34.PubMedPubMedCentralCrossRef
127.
128.
129.
Herman SE, et al. The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemiaACP-196 displays clinical activity in mouse models of CLL. Clin Cancer Res. 2017;23(11):2831–41.PubMedCrossRef
130.
Herman SE, et al. Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia. 2013;27(12):2311–21.PubMedPubMedCentralCrossRef
131.
Khan Y, O’Brien S. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. Future Oncol. 2019;15(6):579–89.PubMedCrossRef
132.
• Byrd JC, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020;135(15):1204–13. The article mentioned about clinical trial of monotherapy in in patients with relapsed/refractory chronic lymphocytic leukemia.PubMedPubMedCentralCrossRef
133.
Blackmon A, O’Brien S. An update on acalabrutinib to treat chronic lymphocytic leukemia. Drugs Today. 2021;57(7):417–31.CrossRef
134.
Sharman JP, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–91.PubMedPubMedCentralCrossRef
135.
Jin Y, et al. A comprehensive review of clinical cardiotoxicity incidence of FDA-approved small-molecule kinase inhibitors. Front Pharmacol. 2020;11:891.PubMedPubMedCentralCrossRef
136.
Byrd JC, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–52.PubMedPubMedCentralCrossRef
137.
Shadman M, et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol. 2023;10(1):e35–45.PubMedCrossRef
138.
139.
Darby SC, et al. Radiation-related heart disease: current knowledge and future prospects. 2010;76(3):656-665.
140.
Curigliano G, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23:vii155–66.PubMedCrossRef
141.
Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270(16):1949–55.PubMedCrossRef
142.
Carr ZA, et al. Coronary heart disease after radiotherapy for peptic ulcer disease. Int J Radiat Oncol Biol Phys. 2005;61(3):842–50.PubMedCrossRef
143.
Kikuchi K, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival. Lancet. 2005;366(9503):2087–106.CrossRef
144.
Tukenova M, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28(8):1308–15.PubMedCrossRef
145.
146.
Metzger ML, et al. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012;307(24):2609–16.PubMedPubMedCentralCrossRef
147.
Tebbi CK, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007;25(5):493–500.PubMedCrossRef
148.
149.
Galper SL, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117(2):412–8.PubMedCrossRef
150.
Aleman BM, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878–86.PubMedCrossRef
151.
Hull MC, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831–7.PubMedCrossRef
152.
Koutroumpakis E, et al. Modern radiotherapy and risk of cardiotoxicity. Chemotherapy. 2020;65(3–4):65–76.PubMedCrossRef
153.
Ebrahimian T, et al. Chronic exposure to external low-dose gamma radiation induces an increase in anti-inflammatory and anti-oxidative parameters resulting in atherosclerotic plaque size reduction in ApoE–/–mice. Radiat Res. 2018;189(2):187–96.PubMedCrossRef
154.
Shao T, et al. Physical activity and nutritional influence on immune function: an important strategy to improve immunity and health status. Front Physiol. 2021;12:751374.PubMedPubMedCentralCrossRef
155.
Myrehaug S, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49(8):1486–93.PubMedCrossRef
156.
Veeragandham RS, Goldin MD. Surgical management of radiation-induced heart disease. Ann Thorac Surg. 1998;65(4):1014–9.PubMedCrossRef
157.
Heidenreich PA, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743–9.PubMedCrossRef
158.
Adams MJ, et al. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol. 2004;22(15):3139–48.PubMedCrossRef
159.
Larsen RL, et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol. 1992;70(1):73–7.PubMedCrossRef
160.
Lipshultz S, Sallan S. Cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol. 1993;11(7):1199–203.PubMedCrossRef
161.
Abdullah CS, et al. Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. Sci Rep. 2019;9(1):2002.PubMedPubMedCentralCrossRef
162.
Karlstaedt A, et al. Glucose 6-phosphate accumulates via phosphoglucose isomerase inhibition in heart muscle. Circ Res. 2020;126(1):60–74.PubMedCrossRef
163.
Ritterhoff J, et al. Metabolic remodeling promotes cardiac hypertrophy by directing glucose to aspartate biosynthesis. Circ Res. 2020;126(2):182–96.PubMedCrossRef
164.
Agnetti G, et al. Modulation of mitochondrial proteome and improved mitochondrial function by biventricular pacing of dyssynchronous failing hearts. Circ Cardiovasc Genet. 2010;3(1):78–87.PubMedCrossRef
165.
Young ME, et al. Proposed regulation of gene expression by glucose in rodent heart. Gene Regul Syst Bio. 2007;1:251–62.PubMedPubMedCentral
166.
Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093–129.PubMedCrossRef
167.
Lopaschuk GD, et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207–58.PubMedCrossRef
168.
169.
Sutendra G, et al. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med. 2013;91:1315–27.PubMedCrossRef
170.
171.
Damiani RM, et al. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch Toxicol. 2016;90:2063–76.PubMedCrossRef
172.
Crouch M-L, et al. Cyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects. PLoS ONE. 2017;12(7):e0181086.PubMedPubMedCentralCrossRef
173.
Căinap SS, et al. The prognostic role of EBER in pediatric cancer. Rom J Morphol Embryol. 2015;56(4):1269–77.PubMed
174.
175.
Racil Z, et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica. 2013;98(10): e124.PubMedPubMedCentralCrossRef
176.
Breccia M, et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res. 2007;31(12):1770–2.PubMedCrossRef
177.
Dreyling M, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–905.PubMedCrossRef
178.
Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94(4):525–33.PubMedCrossRef
179.
180.
Kerkelä R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908–16.PubMedCrossRef
181.
182.
•• Russo M, et al. Metabolic aspects of anthracycline cardiotoxicity. Curr Treat Options Oncol. 2021;22:1–21. Article is highly recommended due to its importance in metabolic aspects of anthracycline-induced cardiotoxicity.CrossRef
183.
184.
Pitt JM, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and-extrinsic factors. Immunity. 2016;44(6):1255–69.PubMedCrossRef
185.
186.
Khunger A, et al. New insights into mechanisms of immune checkpoint inhibitor-induced cardiovascular toxicity. Curr Oncol Rep. 2020;22:1–11.CrossRef
187.
188.
189.
Herbst RS, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.PubMedCrossRef
190.
191.
Lesokhin AM, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698.PubMedPubMedCentralCrossRef
192.
Nayak L, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3.PubMedPubMedCentralCrossRef
193.
194.
Wang J, et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol. 2010;22(6):443–52.PubMedCrossRef
195.
Semper H, et al. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1-negative squamous cell carcinoma of the lung. Lung Cancer. 2016;99:117–9.PubMedCrossRef
196.
197.
Ji C, et al. Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors immune checkpoint inhibitors induce myocarditis in monkeys. Clin Cancer Res. 2019;25(15):4735–48.PubMedCrossRef
198.
199.
Puzanov I, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):1–28.PubMedPubMedCentralCrossRef
200.
Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.PubMedCrossRef
201.
Bloom MW, et al. Cancer therapy–related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail. 2016;9(1):e002661.PubMedPubMedCentralCrossRef
202.
203.
Cardinale D, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910–6.PubMedCrossRef
204.
Cardinale D, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749–54.PubMedCrossRef
205.
206.
Members ATF, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Euro Heart J. 2012;33(14):1787–847.CrossRef
207.
De Iuliis F, et al. Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients. Tumour Biol. 2016;37(3):3379–87.PubMedCrossRef
208.
Witteles R. Biomarkers as predictors of cardiac toxicity from targeted cancer therapies. J Card Fail. 2016;22(6):459–64.PubMedCrossRef
209.
Onitilo AA, et al. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat. 2012;134(1):291–8.PubMedCrossRef
210.
211.
Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938–45.PubMedCrossRef
212.
Lyu YL, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839–46.PubMedCrossRef
213.
Lipshultz SE, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950–61.PubMedPubMedCentralCrossRef
214.
Barbosa RR, et al. Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers. Rev Assoc Med Bras (1992). 2018;64:745–54.PubMedCrossRef
215.
Hutchins KK, et al. Prevention of cardiotoxicity among survivors of childhood cancer. Br J Clin Pharmacol. 2017;83(3):455–65.PubMedCrossRef
Metadata
Title
A Comprehensive Review of Cancer Drug–Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies
Authors
Vincenzo Costanzo, PhD
Yashwant Kumar Ratre, PhD
Emanuela Andretta, PhD
Rakesh Acharya, M.sc Zoology
L. V. K. S. Bhaskar, PhD
Henu Kumar Verma, PhD
Publication date
19-02-2024
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 4/2024
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-023-01175-z

Other articles of this Issue 4/2024

Current Treatment Options in Oncology 4/2024 Go to the issue

ReviewPaper

Role of ctDNA in gynecologic malignancies

ReviewPaper

Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?

ReviewPaper

Pioneering the Way: The Revolutionary Potential of Antibody–Drug Conjugates in NSCLC

ReviewPaper

Treatment Options for Distal Rectal Cancer in the Era of Organ Preservation

ReviewPaper

Update on Dosing and Fractionation for Neoadjuvant Radiotherapy for Localized Soft Tissue Sarcoma

ReviewPaper

Social Determinants of Health and the Link to Colorectal Cancer Outcomes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits